NCT05171816 2026-03-11Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZenecaPhase 3 Active not recruiting110 enrolled 12 charts